7 Jun 2017

  • Buccal administration
  • No first pass-hepatic degradation
  • Passage through the BBB
  • No exposure to plasmatic and interstitial degradation enzymes
  • Increased benefit/risk ratio
  • Superior pharmacokinetic profile with increased efficacy coupled with better tolerability
  • Low COGs through simple but patented manufacturing process
  • Finished product stable for 6 months at 40°C, and 3 years at room temperature for empty formulation
  • Suitable for pediatric use

AONYS® Technology offers major benefits. Active agents are administered through a non-invasive administration (mouth deposit). At the same time, it allows drugs to reach their intracellular targets, in the brain for example, while reducing the required dose and diminishing side effects.